Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 2Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 11Pemetrexed 8Paclitaxel 8Radiotherapy 7Docetaxel 7Bevacizumab 7Cisplatin 6Gemcitabine 5pembrolizumab 3Taxes 3Metformin 3Vinorelbine 2Thalidomide 2Radiotherapy, Conformal 2Nivolumab 2Cetuximab 2trametinib 1sintilimab 1satraplatin 1ribociclib 1pegfilgrastim 1naporafenib 1motexafin gadolinium 1milademetan 1cixutumumab 1atezolizumab 1anetumab ravtansine 1aldesleukin 1Watchful Waiting 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma of Lung × naporafenib × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡